Results 121 to 130 of about 35,569 (305)

Evaluating the Evolving Real‐World Adverse Events of GLP‐1RAs Using FDA Adverse Event Reporting System (FAERS)

Obesity, EarlyView.
Web portal for interrogating Adverse Events of GLP‐1 RA in diabetes vs weight control/obesity. ABSTRACT Objective This study aimed to assess the spectrum and frequency of adverse events (AEs) linked to glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) using the US FDA Adverse Event Reporting System (FAERS).
David Stone, Mary Playdon, Stephen D. Hursting, Aik Choon Tan   +3 more
wiley   +1 more source

Levodopa Efficacy and GLP‐1 Receptor Agonists

Movement Disorders Clinical Practice, EarlyView.
Catherine Martinez, Christine Girges, Thomas Foltynie, Anne‐Marie Wills   +3 more
wiley   +1 more source

Musculoskeletal Outcomes of Glucagon‐Like Peptide‐1 Receptor Agonists Versus Other Antiobesity Agents in Nondiabetic Adults

Obesity, EarlyView.
ABSTRACT Objective This study aimed to evaluate the association of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) with risks of osteoporosis, major osteoporotic fractures, and degenerative musculoskeletal disorders in nondiabetic adults with obesity compared with other obesity medications.
Jie‐Syuan Wu, Lee‐Yuan Lin, Jia‐Wei Sun, Wei‐Ting Yu, Fara Silvia Yuliani, Shyh‐Hsiang Lin   +5 more
wiley   +1 more source

Efficacy and safety of cotadutide, a dual glucagon-like peptide-1 and glucagon receptor agonist, in a randomized phase 2a study of patients with type 2 diabetes and chronic kidney disease

, 2022
Efficacy and safety of cotadutide, a dual glucagon-like peptide-1 and glucagon receptor agonist, in a randomized phase 2a study of patients with type 2 diabetes and chronic kidney ...
Rory J McCrimmon (4965481), Thuong Hoang (13097670), Ludger Rose (6493382), Victoria ER Parker (11283531), Maximillian G Posch (16529841), Yi-Ting Chang (523478), Barbara Wenzel (3079686), Heike Schlichthaar (16529838), Lutz Jermutus (608646), Fraser W Gibb (6664697), Hiddo JL Heerspink (8335752), Philip Ambery (3355787), Marcella Petrone (2472097), Lars Hansen (206874)   +13 more
core  

Incidental Resolution of Dopamine Agonist Induced Impulse Control Disorder with GLP‐1 Receptor Agonist

Movement Disorders Clinical Practice, EarlyView.
Hannah Kelly, Thomas Davis
wiley   +1 more source

Use of Glucagon‐Like Peptide‐1 Receptor Agonists in Danish Adolescents and Young Adults 2018–2025

Obesity, EarlyView.
ABSTRACT Objective Use of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) has increased rapidly following approval for obesity treatment, but data on their use in younger populations remain limited. We examined trends in GLP‐1RA use among 12– to 24‐year‐olds in Denmark during 2018–2025.
Helene Kildegaard, Jacob Harbo Andersen, Rebecca Kofod Vinding, Julie Tonsgaard Kloppenborg, Anton Pottegård   +4 more
wiley   +1 more source

SURMOUNT‐REAL UK: A Pragmatic Randomized Clinical Trial to Assess the Effectiveness of Tirzepatide in Adults With Obesity

Obesity, EarlyView.
ABSTRACT Objective SURMOUNT‐REAL UK will evaluate the effectiveness of tirzepatide when offered in addition to standard‐of‐care (SoC) in adults with Class I obesity (BMI ≥ 30 and ≤ 34.9 kg/m2) and without diabetes in a UK primary care setting. Methods A 5‐year, phase 4, multicenter, open‐label, pragmatic randomized clinical trial is enabled through ...
Martin K. Rutter, Julie Mount, J. Martin Gibson, Joanne Webb, Cheryl Marler, Catherine Reed, Mugdha Gore, Wenyu Ye, Elisa Gomez Valderas, John Wilding, Naveed Sattar, Melanie J. Davies, Kamlesh Khunti, Richard Haynes, Rachel L. Batterham   +14 more
wiley   +1 more source

Efficacy and tolerability of oral semaglutide in Japanese patients with type 2 diabetes mellitus: Analysis report from diabetes specialist clinics

Journal of Diabetes Investigation
Introduction Glucagon‐like peptide 1 receptor agonists (GLP1Ras) have emerged as pivotal agents in diabetes management and organ protection. However, their use is limited due to the necessity for injectable administration.
Tetsuaki Inokuchi, Yoshihide Fukumoto, Gendai Lee, Yoshifumi Yokomizo, Kokichi Tanaka, Michiko Chosa, Masaru Doi, Noboru Tamaki, Seiichi Goto, Kojiro Ichikawa, Kazuo Kobayashi   +10 more
doaj   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists and Chronic Cough

JAMA Otolaryngology–Head & Neck Surgery
Importance Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have become substantially more popular as a medication to treat obesity and type 2 diabetes (T2D). Despite their known association with gastroesophageal reflux disease and vagal nerve stimulation, the association between GLP-1RAs and chronic cough ...
Gallagher, Tyler J., Razura, Diego E., Li, Albert, Kim, Ian, Vukkadala, Neelaysh, Barbu, Anca M.   +5 more
openaire   +2 more sources

Glucagon-Like Peptide-1 Receptor Agonists in Hidradenitis Suppurativa

JAMA Dermatology
This cohort study investigates the potential therapeutic benefits of glucagon-like peptide-1 receptor agonists in patients with hidradenitis suppurativa.
Gouvrion, Louise, Delage, Maïa, P. Villani, Axel, Le Naour, Sarah, Fite, Charlotte, Cassius, Charles, Misery, Laurent, Oules, Bénédicte, Fayad, Alice, Brun, Aurore, Pruvost-Balland, Christelle, Safa, Gilles, Tardieu, Mathilde, Buche, Sebastien, Maruani, A, Quéreux, Gaëlle, Nassif, Aude, Guenego, Agathe, Thibault, Ronan, Dupuy, Alain, Poizeau, Florence   +20 more
openaire   +4 more sources